BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/30/2024 3:48:47 AM | Browse: 259 | Download: 908
Publication Name World Journal of Diabetes
Manuscript ID 99496
Country United Kingdom
ISSN 1948-9358 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Endocrinology & Metabolism
Manuscript Type Editorial
Article Title Current perspectives and the future of disease-modifying therapies in type 1 diabetes
Manuscript Source Invited Manuscript
All Author List Sunetra Mondal and Joseph M Pappachan
ORCID
Author(s) ORCID Number
Sunetra Mondal http://orcid.org/0000-0003-3064-466X
Joseph M Pappachan http://orcid.org/0000-0003-0886-5255
Funding Agency and Grant Number
Corresponding Author Joseph M Pappachan, MD, Professor, Department of Endocrinology and Metabolism, Lancashire Teaching Hospitals NHS Trust, Sharoe Green Lane, Preston PR2 9HT, United Kingdom. drpappachan@yahoo.co.in
Key Words Teplizumab; Type 1 diabetes mellitus; Disease modifying therapy; β-cell function; C-peptide; Immunotherapy
Core Tip Teplizumab is an anti-CD3 immunomodulator that can render the T cell anergic to its target antigen and thus protect against autoimmune beta cell destruction. It is approved for use in individuals aged above 8 years in early pre-clinical stages of type 1 diabetes mellitus to prevent progression to clinical stage (stage 3). C-peptide decline is halted and the need for insulin therapy can be delayed even after discontinuation of this therapeutic molecule. Adverse effects are mostly mild. The high cost and lack of availability limit its applicability in low- and middle-income countries.
Publish Date 2024-11-30 03:48
Citation

Mondal S, Pappachan JM. Current perspectives and the future of disease-modifying therapies in type 1 diabetes. World J Diabetes 2025; 16(1): 99496

URL https://www.wjgnet.com/1948-9358/full/v16/i1/99496.htm
DOI https://dx.doi.org/10.4239/wjd.v16.i1.99496
Full Article (PDF) WJD-16-99496-with-cover.pdf